First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy

Diamond, J. R., Boni, V., Lim, E., Nowakowski, G., Cordoba, R., Morillo, D., Valencia, R., Genvresse, I., Merz, C., Boix, O., Frigault, M. M., Greer, J. M., Hamdy, A. M., Huang, X., Izumi, R., Wong, H., & Moreno, V. (2022). First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy. Clinical Cancer Research, 28(7), 1285–1293. https://doi.org/10.1158/1078-0432.ccr-21-3617
Authors:
Jennifer R. Diamond
Valentina Boni
Emerson Lim
Grzegorz Nowakowski
Raul Cordoba
Daniel Morillo
Ray Valencia
Isabelle Genvresse
Claudia Merz
Oliver Boix
Melanie M. Frigault
Joy M. Greer
Ahmed M. Hamdy
Xin Huang
Raquel Izumi
Harvey Wong
Victor Moreno
Affiliated Authors:
Emerson Lim
Publication Type:
Article
Unique ID:
10.1158/1078-0432.CCR-21-3617
PMID:
Publication Date:
Data Source:
Scopus

Record Created: